Peter Bradding
Overview
Explore the profile of Peter Bradding including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
154
Citations
5917
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Couillard S, Shrimanker R, Chaudhuri R, Mansur A, McGarvey L, Heaney L, et al.
Am J Respir Crit Care Med
. 2021 Jun;
204(6):731-734.
PMID: 34129808
No abstract available.
22.
Babaei-Jadidi R, Dongre A, Miller S, Uribe M, Stewart I, Thompson Z, et al.
Am J Respir Crit Care Med
. 2021 Apr;
204(4):431-444.
PMID: 33882264
Lymphangioleiomyomatosis (LAM) is a multisystem disease that causes lung cysts and respiratory failure. Loss of TSC (tuberous sclerosis complex) gene function results in a clone of "LAM cells" with dysregulated...
23.
Alzahrani A, Hussain A, Alhadian F, Hakeem J, Douaoui S, Tliba O, et al.
Adv Exp Med Biol
. 2021 Mar;
1303:1-12.
PMID: 33788184
The mechanisms driving corticosteroid insensitivity in asthma are still unclear although evidence points toward a potential role of lung mast cells. Indeed, a number of in vitro studies using various...
24.
Virk H, Biddle M, Smallwood D, Weston C, Castells E, Bowman V, et al.
Br J Pharmacol
. 2021 Mar;
178(15):2948-2962.
PMID: 33786825
Background And Purpose: TGFβ1-mediated myofibroblast activation contributes to pathological fibrosis in many diseases including idiopathic pulmonary fibrosis (IPF), where myofibroblast resistance to oxidant-mediated apoptosis is also evident. We therefore investigated...
25.
Boddy C, Naveed S, Craner M, Murphy A, Siddiqui S, Bradding P
J Allergy Clin Immunol Pract
. 2020 Nov;
9(4):1529-1538.e2.
PMID: 33186765
Background: Nonadherence in difficult-to-control asthma can be identified using 7-day FeNO suppression testing where patients take additional fluticasone via Diskus with an Inhaler Compliance Assessment (INCA) acoustic monitoring device attached,...
26.
Busby J, Holweg C, Chai A, Bradding P, Chaudhuri R, Mansur A, et al.
Pulm Pharmacol Ther
. 2020 Oct;
64:101951.
PMID: 33045343
Background And Objective: Non-adherence is an important issue within severe asthma. Prednisolone and cortisol assays have been proposed as an inexpensive, objective measure of adherence for oral corticosteroid (OCS)-dependent asthmatics,...
27.
Heaney L, Busby J, Hanratty C, Djukanovic R, Woodcock A, Walker S, et al.
Lancet Respir Med
. 2020 Sep;
9(1):57-68.
PMID: 32916135
Background: Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce exacerbations. This approach is potentially flawed because symptomatic asthma can occur without corticosteroid responsive type-2 (T2)-driven eosinophilic...
28.
Austin C, Edick M, Ferrando R, Solon M, Baca M, Mesh K, et al.
Clin Exp Allergy
. 2020 Sep;
50(12):1342-1351.
PMID: 32909660
Background: The anti-interleukin 13 (IL-13) monoclonal antibody lebrikizumab improves lung function in patients with moderate-to-severe uncontrolled asthma, but its effects on airway inflammation and remodelling are unknown. CLAVIER was designed...
29.
Majd S, Apps L, Chantrell S, Hudson N, Eglington E, Hargadon B, et al.
J Allergy Clin Immunol Pract
. 2020 Jun;
8(10):3418-3427.
PMID: 32531482
Background: Currently, the acceptability and efficacy of pulmonary rehabilitation for adults with severe asthma is unknown. Objective: To investigate the feasibility of performing a randomized controlled trial of asthma-tailored pulmonary...
30.
Bradding P, Richardson M, Hinks T, Howarth P, Choy D, Arron J, et al.
J Allergy Clin Immunol
. 2020 May;
146(1):208-211.
PMID: 32450087
No abstract available.